We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
+7.32%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$830M
AUM Growth
-$75.9M
Cap. Flow
+$93.8M
Cap. Flow %
11.3%
Top 10 Hldgs %
95.96%
Holding
17
New
–
Increased
2
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$164M
2
DYN icon
Dyne Therapeutics
DYN
+$10.8M

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$23.8M
2
REPL icon
Replimune Group
REPL
+$21M
3
AKRO
Akero Therapeutics
AKRO
+$17.1M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$12.3M
5
JBIO
Jade Biosciences
JBIO
+$6.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
1
DELISTED
Day One Biopharmaceuticals
DAWN
$163M 19.62%
7,568,317
-600,854
-7% -$12.3M
KYMR icon
2
Kymera Therapeutics
KYMR
$8.51B
$149M 17.99%
5,984,736
-890,962
-13% -$23.8M
DYN icon
3
Dyne Therapeutics
DYN
$4.7B
$114M 13.78%
9,869,483
+934,581
+10% +$10.8M
VIGL
4
DELISTED
Vigil Neuroscience
VIGL
$73M 8.79%
5,836,874
– –
IRON icon
5
Disc Medicine
IRON
$2.96B
$68.9M 8.29%
3,461,784
+3,286,638
+1,877% +$164M
JBIO
6
Jade Biosciences
JBIO
$1.2B
$59.1M 7.12%
57,643
-8,869
-13% -$6.44M
REPL icon
7
Replimune Group
REPL
$941M
$57.1M 6.87%
2,098,300
-1,010,000
-32% -$21M
THRD
8
DELISTED
Third Harmonic Bio
THRD
$46.9M 5.65%
10,907,859
– –
AKRO
9
DELISTED
Akero Therapeutics
AKRO
$32.6M 3.92%
594,251
-400,000
-40% -$17.1M
GBIO
10
DELISTED
Generation Bio
GBIO
$32.5M 3.92%
827,888
– –
IMA
11
ImageneBio Inc
IMA
$63M
$13.3M 1.61%
418,182
– –
XLO icon
12
Xilio Therapeutics
XLO
$59.9M
$7.42M 0.89%
197,096
– –
FSTX
13
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.79M 0.46%
599,524
– –
TECX
14
Tectonic Therapeutic
TECX
$529M
$3.22M 0.39%
376,739
– –
VRDN icon
15
Viridian Therapeutics
VRDN
$2.09B
$2.63M 0.32%
90,072
– –
SPRO icon
16
Spero Therapeutics
SPRO
$67.7M
$1.78M 0.21%
1,031,160
– –
DNTH icon
17
Dianthus Therapeutics
DNTH
$5.84B
$1.37M 0.17%
217,284
– –

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Atlas Venture Life Science Advisors held 17 positions worth $830M, down 8.4% from $906M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Atlas Venture Life Science Advisors deployed $93.8M of net new capital in Q4 2022, adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Kymera Therapeutics, an estimated $23.8M trimmed.

  • Atlas Venture Life Science Advisors added most to Disc Medicine in Q4 2022, an estimated $164M increase.
  • Atlas Venture Life Science Advisors's biggest Q4 2022 reduction was Kymera Therapeutics, cutting an estimated $23.8M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 96% of its $830M portfolio in Q4 2022.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 0 in Q4 2022.
  • Atlas Venture Life Science Advisors's portfolio value fell 8.4% quarter-over-quarter to $830M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.